Bezafibrate

Structural formula
General
Non-proprietary name	Bezafibrate
other names	2- (4- {2 - [(4-chlorobenzoyl) amino] ethyl} phenoxy) -2-methylpropionic acid ( IUPAC )
Molecular formula	C 19 H 20 ClNO 4
Brief description	white crystalline powder
External identifiers / databases
EC number	255-567-9
ECHA InfoCard	100,050,498
PubChem	39042
ChemSpider	35728
DrugBank	DB01393
Wikidata	Q577387
Drug information
ATC code	C10 AB02
Drug class	Fibrates
properties
Molar mass	361.82 g · mol -1
solubility	practically insoluble in water; soluble in DMF and methanol ;
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS labeling of hazardous substances Caution
H and P phrases	H: 302
	P: no P-phrases
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Bezafibrate is an active ingredient from the group of fibrates . It lowers the triglycerides and the low density lipoproteins and increases the high density lipoproteins . Boehringer Mannheim introduced the active ingredient in 1977 (trade name: Cedur ).

Like other fibrates, bezafibrate acts as an agonist of the peroxisome proliferator-activated receptor PPARα . According to some studies, it also affects the activity of PPARγ and PPARδ.

Common side effects include loss of appetite. In rare cases, myopathy , acute renal failure , dizziness and cholestasis have been reported. In very rare cases, rhabdomyolysis , gallstones and changes in the blood count have also been reported.

A newer treatment indication, for which the drug has not yet been officially approved, is emerging in the treatment of primary biliary cholangitis (PBC). It is considerably cheaper and seems to be as effective as the newly developed obeticholic acid.

literature

I. Goldenberg, M. Benderly, U. Goldbourt: Update on the use of fibrates: focus on bezafibrate. In: Vascular health and risk management. Volume 4, Number 1, 2008, pp. 131-141, PMID 18629356 . PMC 2464751 (free full text) (review).

Web links

Bezafibrate . In: drugs from A-Z .

Individual evidence

↑ ^a ^b ^c ^d ^e Bezafibrate data sheet at Sigma-Aldrich , accessed on February 23, 2013 ( PDF ).

↑ Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study . PMID 10880410

↑ Christophe Corpechot, Olivier Chazouillères, Alexandra Rousseau, Antonia Le Gruyer, François Habersetzer: A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis . In: New England Journal of Medicine . June 6, 2018, doi : 10.1056 / NEJMoa1714519 ( nejm.org [accessed December 10, 2018]).

[Sigma-1] Bezafibrate data sheet at Sigma-Aldrich , accessed on February 23, 2013 ( PDF ).

[2] Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study . PMID 10880410

[3] Christophe Corpechot, Olivier Chazouillères, Alexandra Rousseau, Antonia Le Gruyer, François Habersetzer: A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis . In: New England Journal of Medicine . June 6, 2018, doi : 10.1056 / NEJMoa1714519 ( nejm.org [accessed December 10, 2018]).